Mandate

Vinge has advised KCG in connection with the acquisition of Neonet

September 16, 2016

Vinge has advised KCG Holdings, Inc. on its acquisition of Neonet Securities AB from inter alios Hay Tor Capital LLP, KAS Bank N.V., Nordic Capital / Cidron Delphi Intressenter AB and Neonet management. Neonet is a Swedish independent capital markets services provider offering a comprehensive suite of advanced algorithmic trading, smart order routing and sales.

KCG is a leading independent securities firm offering investors a range of services designed to address trading needs across asset classes, product types and time zones. The acquisition is a strategic supplement to KCG’s business concept and will strengthen KCG’s reach in continental Europe and will enable both KCG’s and Neonet’s clients to access a more complete range of international execution services and capabilities.

The acquisition was granted the relevant approvals from the Swedish Financial Supervisory Authority on 6 September and was completed on 14 September 2016.

Vinge’s team consisted of among others partners Daniel Rosvall (M&A) and Emma Stuart-Beck (Financial Services) as well as associates Samra Baytar (M&A), Caroline Krassén and Henrik Schön (Financial Services).


 

Related

Vinge advises Axcel VI and Currentum in connection with the acquisition of Elprojekt Skandinavien

Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of Elprojekt Skandinavien. The company provides complete electrical installations throughout Sweden, focusing on new construction of logistics properties, production facilities, residential buildings and office buildings. Elprojekt Skandinavien had a revenue of SEK 316 million in 2024.
June 23, 2025

Vinge advises Meribel Pharma Solutions

Vinge advises Meribel Pharma Solutions in connection with the sale of a production facility specialising in the manufacture of antibiotics to Apotek Produktion & Laboratorier AB ("APL").
June 23, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 232 million and restructuring of debt financing

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue, through which Hansa raises gross proceeds of approx. SEK 232 million, and restructuring of debt financing. As part of such debt restructuring, Hansa has in conjunction with the directed share issue set-off debt corresponding to approximately USD 14.9 million of its total debt amount.
June 23, 2025